HomeMy WebLinkAbout2020-479-E Health-NC Division of Public Health 539 addendumDivision of Public Health
Agreement Addendum
FY 20-21
Page 1 of 5
_____________________________________________ ____________________________________
Health Director Signature (use blue ink) Date
Local Health Department to complete:
(If follow-up information is needed by DPH) LHD program contact name:
Phone number with area code:
Email address:
Signature on this page signifies you have read and accepted all pages of this document. Revised June 2019
Orange County Health Department Epidemiology / Communicable Disease Branch
Local Health Department Legal Name DPH Section / Branch Name
539 COVID-19 CARES Activities
Vanessa M. Greene 919-546-1658
vanessa.greene@dhhs.nc.gov
Activity Number and Description DPH Program Contact
(name, phone number, and email)
01/20/2020 – 05/31/2021
Service Period DPH Program Signature Date
(only required for a negotiable agreement addendum)
07/01/2020 – 06/30/2021
Payment Period
Original Agreement Addendum
Agreement Addendum Revision #
I. Background:
The primary mission of the Communicable Disease Branch (CDB) is to reduce morbidity and mortality
resulting from communicable diseases that are a significant threat to the public through detection,
investigation, testing, treatment, tracking, control, education, and care activities to improve the health of
people in North Carolina.
As part of the “Coronavirus Aid, Relief, and Economic Security Act” or the “CARES Act” of 2020, the
Centers for Disease Control and Prevention’s (CDC’s) Epidemiology and Laboratory Capacity (ELC)
CARES cooperative agreement is awarding a total of nearly $631 million to our recipient base in a
program-initiated component funding under the Emerging Issues (E) Project of CK19-1904, henceforth
“ELC CARES.” The intention of this funding is to rapidly establish and monitor key activities related to
COVID-19 in the areas of epidemiology, laboratory, and informatics. Monitoring the indicators
associated with these activities are intended to assist State, local, and territorial governments in making
data-driven policy decisions regarding testing, mitigation, and prevention efforts.
The Division of Public Health (DPH), Communicable Disease Branch (CDB), is making an allocation of
these funds available to all local health departments through the “CDC-RFA-TP18-1802, Cooperative
Agreement for Emergency Response: Public Health Crisis Response, COVID-19 Crisis Response
Cooperative Agreement – Components A and B Supplemental Funding” to carry out surveillance,
epidemiology, laboratory capacity, infection control, mitigation, communications, and other
preparedness and response activities.
nbontrager@orangecountync.gov
919-245-2407
Natalie Bontrager
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
7/30/2020
Page 2 of 5
Revised June 2019
II. Purpose:
This Activity is for the Local Health Department to work to prevent, prepare for, and respond to
Coronavirus Disease 2019 (COVID-19) by carrying out surveillance, epidemiology, laboratory capacity,
infection control, mitigation, communications, and other preparedness and response activities.
III. Scope of Work and Deliverables:
All of the activities the Local Health Department performs under this Agreement Addendum shall
be informed by the NC DHHS COVID-19 Guidance for Health Care Providers and Local Health
Departments.1 The Local Health Department (LHD) shall identify and address one or more of the
allowable activities from the list of five activities below, with an emphasis on testing and tracing:
1. Testing and Tracing: Establish or enhance ability to aggressively identify cases, conduct
contact tracing and follow up, as well as implement recommended containment measures.
a. Enhanced testing and contact tracing including contact elicitation/identification, contact
notification, and contact follow-up. Activities could include traditional contact tracing methods
as well as healthcare-specific and other proximity/location-based methods.
2. Surveillance: Improve morbidity and mortality surveillance, including:
a. Establish or enhance community-based surveillance i.e., surveillance of populations and
individuals without severe illness, travel to high-risk locations, or contacts to known cases.
b. Provide accurate accounting of COVID-19 associated deaths. Maintain electronic death reporting
using the North Carolina Electronic Disease Surveillance System (NCEDSS).
3. Lab Capacity: Enhance laboratory testing and reporting capacity:
a. Establish or expand capacity to test all symptomatic individuals, and secondarily expand
capacity to achieve community-based surveillance.
4. Infection Control: Prevent and control COVID-19 in healthcare settings and protect other
vulnerable or high-risk populations:
a. Assess and monitor infections in healthcare workers across the healthcare spectrum.
b. Monitor and help implement mitigation strategies for COVID-19 in all high-risk healthcare
facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, other long-term care
facilities).
c. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g.,
meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters).
5. Community Risk Assessment: Improve understanding of jurisdictional communities with
respect to COVID-19 risk:
a. Build understanding of population density and high-risk population density (i.e., population of
>65 years, proportion of population with underlying conditions, households with limited English
fluency, healthcare seeking behavior, populations without insurance and below poverty level).
1 https://www.ncdhhs.gov/divisions/public-health/covid19/covid-19-guidance#all-guidance-for-health-care-providers-and-local-
health-departments
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
Page 3 of 5
Revised June 2019
IV. Performance Measures/Reporting Requirements:
1. Performance Measures
a. Performance Measure # 1: The LHD shall have a policy to ensure access to COVID-19 testing
for all symptomatic persons and for those who have had close contact to a known or suspected
case of COVID-19 as defined by the CDC, and for those who request or require testing.
Reporting Requirements: An electronic copy of this testing policy shall be provided to the
Regional Communicable Disease Nurse Consultant no later than September 1, 2020.
b. Performance Measure # 2: The LHD shall report cases of COVID-19 including deaths within
30 days of receipt of the report to the state disease registrar via the NC EDSS.
Reporting Requirements: Reporting will be done via the NC EDSS.
c. Performance Measure # 3: The LHD shall report COVID-19 activity (decline, no change, and
increase) in high-risk healthcare facilities (e.g., nursing homes, dialysis centers, long-term care
facilities) and congregate living settings (e.g., prisons, youth homes, shelters) via the NCEDSS
outbreak module and the CD Outbreak Worksheet within 2 days of receipt of outbreak.
Reporting Requirements: Reporting will be done via the NC EDSS and consultation as needed
by CDB staff.
d. Performance Measure #4: The LHD shall report close contacts to COVID-19 into the COVID-
19 Community Team Outreach (CCTO) Tool software for at least 60% of people infected with
COVID-19.
Reporting Requirements: Reporting will be done via the CCTO tool software
e. Performance Measure #5: The LHD shall complete the Final Monitoring Outcome variable for
90% of contacts entered after 14 days.
Reporting Requirements: Reporting will be done via the CCTO tool software.
2. Additional Reporting Requirements
a. The LHD shall submit Annual Reports to include progress of work performed against each of the
allowable activities and performance measures, data (numbers tested/traced to during reporting
period), as well as use of funds and programmatic reporting to the CDB at the following
intervals:
FY19-20 (January–May 2020) report due no later than August 15, 2020
FY 20-21 (June 2020–May 2021) report due no later than June 15, 2021
b. Provide data, plans, and documents as requested by CDB that supports reporting the performance
measures and deliverables from the ELC CARES grant. Plans and other documents must be
consistent with state and federal requirements and must be specific to the LHD’s local public
health jurisdiction.
c. The LHD will submit an annual report via Survey Monkey which will include the reporting of
work performed against each of the allowable activities and performance measures, data
(numbers tested and numbers of contacts traced during the reporting period), reporting on the use
of funds, and programmatic reporting. The Survey Monkey survey link will be sent to the LHD
by CDB no later than June 15, 2021.
V. Performance Monitoring and Quality Assurance:
1. The TATP Nurse Consultant will assess the Local Health Department’s performance through
reporting mechanisms within the NC EDSS. These reports will be run on a quarterly basis by the
TATP Nurse Consultant.
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
Page 4 of 5
Revised June 2019
2. If the assessment results in compliance concerns, the TATP Nurse Consultant shall conduct
conference calls with the Local Health Department to provide technical assistance in order to rectify
the concerns.
VI. Funding Guidelines or Restrictions:
1. Requirements for pass-through entities: In compliance with 2 CFR §200.331 – Requirements for
pass-through entities, the Division of Public Health provides Federal Award Reporting Supplements
to the Local Health Department receiving federally funded Agreement Addenda.
a. Definition: A Supplement discloses the required elements of a single federal award. Supplements
address elements of federal funding sources only; state funding elements will not be included in
the Supplement. Agreement Addenda (AAs) funded by more than one federal award will receive
a disclosure Supplement for each federal award.
b. Frequency: Supplements will be generated as the Division of Public Health receives information
for federal grants. Supplements will be issued to the Local Health Department throughout the
state fiscal year. For federally funded AAs, Supplements will accompany the original AA. If
AAs are revised and if the revision affects federal funds, the AA Revisions will include
Supplements. Supplements can also be sent to the Local Health Department even if no change is
needed to the AA. In those instances, the Supplements will be sent to provide newly received
federal grant information for funds already allocated in the existing AA.
2. Expenses related to allowable activities may be reimbursed retroactively to January 20, 2020.
3. As the Local Health Department is a subrecipient of a grant or cooperative agreement awarded by the
Department of Health and Human Services (HHS) with funds made available under the Coronavirus
Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus
Aid, Relief, and Economic Security Act, 2020 (the “CARES Act”) (P.L. 116-136); and/or the Paycheck
Protection Program and Health Care Enhancement Act (P.L. 116-139) the LHD agrees as applicable to
the award, to:
a. comply with existing and/or future directives and guidance from the HHS Secretary regarding control
of the spread of COVID-19;
b. in consultation and coordination with HHS, provide, commensurate with the condition of the
individual, COVID-19 patient care regardless of the individual’s home jurisdiction and/or
appropriate public health measures (e.g., social distancing, home isolation); and
c. assist the United States Government in the implementation and enforcement of federal orders related
to quarantine and isolation. In addition, to the extent applicable, Recipient will comply with Section
18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests
intended to detect SARS– CoV–2 or to diagnose a possible case of COVID–19. Such reporting shall
be in accordance with guidance and direction from HHS and/or CDC.
d. consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this
award, and the underlying funding, the subrecipient is expected to provide to CDC, through DPH,
copies of and/or access to COVID-19 data collected with these funds, including but not limited to
data related to COVID-19 testing. CDC will specify in further guidance and directives what is
encompassed by this requirement.
4. In addition to their local procurement rules/policies, the Local Health Department shall comply with the
following rules, applying the most restrictive standard where there is a difference between any of the
standards:
a. Federal Uniform Administrative Requirements for Procurement, 45 CFR Part 75 §75.327-
335, https://www.ecfr.gov/cgi-bin/text-idx?node=pt45.1.75&rgn=div5#se45.1.75_1326
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
Page 5 of 5
Revised June 2019
i. Appendix II to Part 75—Contract Provisions for Non-Federal Entity Contracts Under
Federal Awards may be found here for incorporation into procurement
contracts: https://www.ecfr.gov/cgi-bin/text-
idx?node=pt45.1.75&rgn=div5#ap45.1.75_1521.ii
5. Unallowable costs:
a. Research
b. Clinical Care
c. Publicity and propaganda (lobbying):
i. Other than for normal and recognized executive-legislative relationships, no funds may
be used for:
1. publicity or propaganda purposes, for the preparation, distribution, or use of any
material designed to support or defeat the enactment of legislation before any
legislative body
2. the salary or expenses of any grant or contract recipient, or agent acting for such
recipient, related to any activity designed to influence the enactment of
legislation, appropriations, regulation, administrative action, or Executive order
proposed or pending before any legislative body
ii. See Additional Requirement (AR) 12 for detailed guidance on this prohibition and
additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-
Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
d. All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically
amended, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost
Principles, And Audit Requirements for HHS Awards.
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
Federal Award Reporting Requirements for Pass-Through Agencies, 2 CFR § 200.331 DPH v3.1 5-9-19
FY21 Activity: COVID-19 CARES Activities Supplement 1
Supplement reason: ☒ In AA+BE or AA+BE Rev –OR– ☐ –
CFDA #: 93.323 Federal awd date: 06/21/20 Is award R&D? no FAIN: NU50CK000530 Total amount of fed awd: $ 209976190
CFDA
name:
Epidemiology and Laboratory Capacity for Infectious
Diseases (ELC)
Fed award
project
description:
CK19-1904 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging
Infectious Diseases (ELC)
Fed awarding
agency:
DHHS, Centers for Disease Control and
Prevention
Federal award
indirect cost rate: n/a %
%
Subrecipient Subrecipient
DUNS
Fed funds for
This Supplement
Total of All Fed Funds
for This Activity Subrecipient Subrecipient
DUNS
Fed funds for
This Supplement
Total of All Fed Funds
for This Activity
Alamance 965194483 60,231 60,231 Jackson 019728518 26,894 26,894
Albemarle 130537822 163,727 163,727 Johnston 097599104 69,230 69,230
Alexander 030495105 25,397 25,397 Jones 095116935 17,768 17,768
Anson 847163029 21,864 21,864 Lee 067439703 31,524 31,524
Appalachian 780131541 71,082 71,082 Lenoir 042789748 30,433 30,433
Beaufort 091567776 27,886 27,886 Lincoln 086869336 38,004 38,004
Bladen 084171628 24,382 24,382 Macon 070626825 24,799 24,799
Brunswick 091571349 52,214 52,214 Madison 831052873 21,070 21,070
Buncombe 879203560 85,862 85,862 MTW 087204173 55,770 55,770
Burke 883321205 39,810 39,810 Mecklenburg 074498353 310,415 310,415
Cabarrus 143408289 71,770 71,770 Montgomery 025384603 22,497 22,497
Caldwell 948113402 37,608 37,608 Moore 050988146 41,978 41,978
Carteret 058735804 34,189 34,189 Nash 050425677 40,875 40,875
Caswell 077846053 21,427 21,427 New Hanover 040029563 78,040 78,040
Catawba 083677138 58,018 58,018 Northampton 097594477 20,596 20,596
Chatham 131356607 35,158 35,158 Onslow 172663270 68,945 68,945
Cherokee 130705072 22,946 22,946 Orange 139209659 54,514 54,514
Clay 145058231 18,164 18,164 Pamlico 097600456 18,626 18,626
Cleveland 879924850 41,910 41,910 Pender 100955413 31,874 31,874
Columbus 040040016 30,315 30,315 Person 091563718 25,914 25,914
Craven 091564294 43,119 43,119 Pitt 080889694 63,435 63,435
Cumberland 123914376 105,052 105,052 Polk 079067930 20,845 20,845
Dare 082358631 25,042 25,042 Randolph 027873132 54,110 54,110
Davidson 077839744 60,626 60,626 Richmond 070621339 27,269 27,269
Davie 076526651 26,665 26,665 Robeson 082367871 50,721 50,721
Duplin 095124798 31,224 31,224 Rockingham 077847143 39,903 39,903
Durham 088564075 99,460 99,460 Rowan 074494014 53,490 53,490
Edgecombe 093125375 29,311 29,311 Sampson 825573975 32,395 32,395
Foothills 782359004 61,160 61,160 Scotland 091564146 24,702 24,702
Forsyth 105316439 117,143 117,143 Stanly 131060829 32,189 32,189
Franklin 084168632 33,461 33,461 Stokes 085442705 27,614 27,614
Gaston 071062186 74,989 74,989 Surry 077821858 34,878 34,878
Graham 020952383 17,358 17,358 Swain 146437553 18,920 18,920
Granville-Vance 063347626 58,898 58,898 Toe River 113345201 59,042 59,042
Greene 091564591 20,707 20,707 Transylvania 030494215 24,531 24,531
Guilford 071563613 160,040 160,040 Union 079051637 78,099 78,099
Halifax 014305957 28,993 28,993 Wake 019625961 305,488 305,488
Harnett 091565986 51,147 51,147 Warren 030239953 20,447 20,447
Haywood 070620232 32,057 32057 Wayne 040036170 48,849 48,849
Henderson 085021470 46,719 46,719 Wilkes 067439950 33,977 33,977
Hoke 091563643 29,665 29,665 Wilson 075585695 37,244 37,244
Hyde 832526243 16,411 16,411 Yadkin 089910624 25,342 25,342
Iredell 074504507 63,613 63,613
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6
7/8/2020
07/08/2020
07/08/2020
DocuSign Envelope ID: 7198D781-BEA6-4795-A20A-3948F519ECD6